{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:24:54Z","timestamp":1794306294776,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012318"],"award-info":[{"award-number":["2022A1515012318"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.euo.2023.10.003","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T15:29:14Z","timestamp":1698161354000},"page":"760-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Gu\u00e9rin\u2013exposed Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Xingliang","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2332-605X","authenticated-orcid":false,"given":"Zhicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taonong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zike","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangjun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.10.003_b0005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/medicina57080749","article-title":"Bladder cancer: current challenges and future directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.euo.2023.10.003_b0010","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2023.10.003_b0015","doi-asserted-by":"crossref","first-page":"42.e13","DOI":"10.1016\/j.urolonc.2013.05.004","article-title":"Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC","volume":"32","author":"Ding","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.10.003_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0025","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2023.10.003_b0030","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-\u03b12b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0040","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0050","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.euo.2023.10.003_b0055","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","article-title":"5-Year outcome of a randomized prospective study comparing bacillus Calmette-Gu\u00e9rin with epirubicin and interferon-\u03b12b in patients with T1 bladder cancer","volume":"191","author":"Hemdan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0060","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin\u2013exposed high-risk non\u2013muscle-invasive bladder cancer","volume":"82","author":"Roumiguie","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell exhaustion and urinary tumor DNA levels are associated with bacillus Calmette-Gu\u00e9rin failure in patients with non\u2013muscle-invasive bladder cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bju.15608","article-title":"Incidence of and mortality from bacille Calmette-Gu\u00e9rin (BCG) infections after BCG instillation therapy","volume":"129","author":"Nurminen","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2023.10.003_b0080","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0085","doi-asserted-by":"crossref","first-page":"615091","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.euo.2023.10.003_b0090","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2023.10.003_b0095","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3892\/etm.2022.11640","article-title":"Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: a retrospective single-center experience","volume":"24","author":"Bai","year":"2022","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.euo.2023.10.003_b0100","doi-asserted-by":"crossref","first-page":"25433","DOI":"10.18632\/oncotarget.15989","article-title":"Human epidermal growth factor receptor 2 expression is more important than bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer","volume":"8","author":"Cormio","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2023.10.003_b0105","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2023.10.003_b0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2003.08.027","article-title":"HER2\/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?","volume":"40","author":"Latif","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2023.10.003_b0115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0125","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/cid\/ciz1080","article-title":"Early vaccination with bacille Calmette-Guerin-Denmark or BCG-Japan versus BCG-Russia to healthy newborns in Guinea-Bissau: a randomized controlled trial","volume":"71","author":"Schaltz-Buchholzer","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.euo.2023.10.003_b0130","first-page":"44","article-title":"Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline","volume":"9","author":"Jin","year":"2022","journal-title":"Mil Med Res"},{"key":"10.1016\/j.euo.2023.10.003_b0135","first-page":"312","article-title":"Evaluation of HER-2\/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay","volume":"135","author":"Goud","year":"2012","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.euo.2023.10.003_b0140","unstructured":"Tumor Pathology Committee of the Chinese Anti-Cancer Association, Expert Committee on Urothelial Carcinoma of the Chinese Society of Clinical Oncology. [Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China]. Zhonghua Zhong Liu Za Zhi 2021;43:1001\u20136."},{"key":"10.1016\/j.euo.2023.10.003_b0145","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1007\/s00345-021-03653-1","article-title":"Association of patients\u2019 sex with treatment outcomes after intravesical bacillus Calmette-Gu\u00e9rin immunotherapy for T1G3\/HG bladder cancer","volume":"39","author":"D\u2019Andrea","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2023.10.003_b0150","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1464-410X.2009.09190.x","article-title":"Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder","volume":"106","author":"Bolenz","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2023.10.003_b0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","article-title":"Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis","volume":"47","author":"Zhao","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euo.2023.10.003_b0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.10.003_b0165","doi-asserted-by":"crossref","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.euo.2023.10.003_b0170","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","article-title":"HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity","volume":"21","author":"Wu","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.euo.2023.10.003_b0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000356201","article-title":"HER2 expression and PI3K-Akt pathway alterations in gastric cancer","volume":"89","author":"Sukawa","year":"2014","journal-title":"Digestion"},{"key":"10.1016\/j.euo.2023.10.003_b0180","first-page":"1215","article-title":"Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells","volume":"2","author":"Kumar","year":"1996","journal-title":"Clin Cancer Res"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:34:38Z","timestamp":1794303278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123002195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2588931123002195"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.10.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Gu\u00e9rin\u2013exposed Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}